Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 9737483, 14 pages
http://dx.doi.org/10.1155/2016/9737483
Review Article

Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility

1Department of Biochemistry, Bowen University, Iwo, Nigeria
2Discipline of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, Westville Campus, Private Bag X54001, University Road, Durban 4000, South Africa
3Nutrition and Chronic Disease Research Unit, Oxidative Stress Research Centre, Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, South Africa

Received 11 May 2016; Revised 15 August 2016; Accepted 26 October 2016

Academic Editor: Mark A. Yorek

Copyright © 2016 Omolola R. Oyenihi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Lançon, N. Hanet, B. Jannin et al., “Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes,” Drug Metabolism and Disposition, vol. 35, no. 5, pp. 699–703, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. U. Stervbo, O. Vang, and C. Bonnesen, “A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine,” Food Chemistry, vol. 101, no. 2, pp. 449–457, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Bastianetto, C. Ménard, and R. Quirion, “Neuroprotective action of resveratrol,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1852, no. 6, pp. 1195–1201, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Catalgol, S. Batirel, Y. Taga, and N. K. Ozer, “Resveratrol: french paradox revisited,” Frontiers in Pharmacology, vol. 3, article 141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. G. A. Potter, L. H. Patterson, E. Wanogho et al., “The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1b1,” British Journal of Cancer, vol. 86, no. 5, pp. 774–778, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Ashikawa, S. Majumdar, S. Banerjee, A. C. Bharti, S. Shishodia, and B. B. Aggarwal, “Piceatannol inhibits TNF-induced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation,” Journal of Immunology, vol. 169, no. 11, pp. 6490–6497, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Wieder, A. Prokop, B. Bagci et al., “Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts,” Leukemia, vol. 15, no. 11, pp. 1735–1742, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Ovesná and K. Horváthová-Kozics, “Structure-activity relationship of trans-resveratrol and its analogues,” Neoplasma, vol. 52, no. 6, pp. 450–455, 2005. View at Google Scholar · View at Scopus
  9. K. R. Patel, V. A. Brown, D. J. L. Jones et al., “Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients,” Cancer Research, vol. 70, no. 19, pp. 7392–7399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Quincozes-Santos, L. D. Bobermin, A. Latini et al., “Resveratrol protects C6 astrocyte cell line against hydrogen peroxide-induced oxidative stress through heme oxygenase 1,” PLoS ONE, vol. 8, no. 5, Article ID e64372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. J. L. Bitterman and J. H. Chung, “Metabolic effects of resveratrol: addressing the controversies,” Cellular and Molecular Life Sciences, vol. 72, no. 8, pp. 1473–1488, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Ciddi and D. Dodda, “Therapeutic potential of resveratrol in diabetic complications: in vitro and in vivo studies,” Pharmacological Reports, vol. 66, no. 5, pp. 799–803, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. B. N. M. Zordoky, I. M. Robertson, and J. R. B. Dyck, “Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1852, no. 6, pp. 1155–1177, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. M. Poulsen, K. Fjeldborg, M. J. Ornstrup, T. N. Kjær, M. K. Nøhr, and S. B. Pedersen, “Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1852, no. 6, pp. 1124–1136, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Jiang, L. Guo, B.-Y. Li et al., “Resveratrol attenuates early diabetic nephropathy by down-regulating glutathione S-transferases Mu in diabetic rats,” Journal of Medicinal Food, vol. 16, no. 6, pp. 481–486, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. K. Bhatt, S. Thomas, and M. J. Nanjan, “Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus,” Nutrition Research, vol. 32, no. 7, pp. 537–541, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. D. O. Kennedy, E. L. Wightman, J. L. Reay et al., “Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation,” American Journal of Clinical Nutrition, vol. 91, no. 6, pp. 1590–1597, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Rivière, T. Richard, X. Vitrac, J.-M. Mérillon, J. Valls, and J.-P. Monti, “New polyphenols active on β-amyloid aggregation,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 2, pp. 828–831, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. C.-C. Chang, C.-Y. Chang, Y.-T. Wu, J.-P. Huang, T.-H. Yen, and L.-M. Hung, “Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase,” Journal of Biomedical Science, vol. 18, no. 1, article no. 47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Kubota, Y. Ozawa, T. Kurihara et al., “Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation,” Investigative Ophthalmology and Visual Science, vol. 52, no. 12, pp. 9142–9148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. S. Yar, S. Menevse, and E. Alp, “The effects of resveratrol on cyclooxygenase-1 and -2, nuclear factor kappa beta, matrix metalloproteinase-9, and sirtuin 1 mRNA expression in hearts of streptozotocin-induced diabetic rats,” Genetics and Molecular Research, vol. 10, no. 4, pp. 2962–2975, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Guo, B. Liu, K. Wang, S. Zhou, W. Li, and Y. Xu, “Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-κB pathway,” Diabetes and Vascular Disease Research, vol. 11, no. 2, pp. 92–102, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Wang, Q. Yang, Y.-Y. Sun et al., “Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice,” Journal of Cellular and Molecular Medicine, vol. 18, no. 8, pp. 1599–1611, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Palsamy and S. Subramanian, “Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1812, no. 7, pp. 719–731, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Xu, Y. Wang, W. Cui et al., “Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-κB pathway,” International Journal of Endocrinology, vol. 2014, Article ID 289327, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. IDF, IDF Diabetes Atlas, 7th edition, 2015.
  27. M. J. Fowler, “Microvascular and macrovascular complications of diabetes,” Clinical Diabetes, vol. 26, no. 2, pp. 77–82, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 32, supplement 1, pp. S62–S67, 2009. View at Publisher · View at Google Scholar
  29. S. E. Kahn, “The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes,” Diabetologia, vol. 46, no. 1, pp. 3–19, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. J. C. Michael, M. C. James, and V. K. Robbins, “Pathalogic basis of disease,” in The Pancreas, pp. 902–929, Harcourt, 6th edition, 2000. View at Google Scholar
  31. A. B. Oyenihi, A. O. Ayeleso, E. Mukwevho, and B. Masola, “Antioxidant strategies in the management of diabetic neuropathy,” BioMed Research International, vol. 2015, Article ID 515042, 15 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Szkudelski and K. Szkudelska, “Resveratrol and diabetes: from animal to human studies,” Biochimica et biophysica acta, vol. 1852, no. 6, pp. 1145–1154, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Ambade and P. Mandrekar, “Oxidative stress and inflammation: essential partners in alcoholic liver disease,” International Journal of Hepatology, vol. 2012, Article ID 853175, 9 pages, 2012. View at Publisher · View at Google Scholar
  34. B. Halliwell and M. Whiteman, “Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?” British Journal of Pharmacology, vol. 142, no. 2, pp. 231–255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. S. D. M. Bandeira, L. J. S. da Fonseca, G. D. S. Guedes, L. A. Rabelo, M. O. F. Goulart, and S. M. L. Vasconcelos, “Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus,” International Journal of Molecular Sciences, vol. 14, no. 2, pp. 3265–3284, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Z. Hasnain, J. B. Prins, and M. A. McGuckin, “Oxidative and endoplasmic reticulum stress in beta-cell dysfunction in diabetes,” Journal of Molecular Endocrinology, vol. 56, no. 2, pp. R33–R54, 2016. View at Publisher · View at Google Scholar
  37. F. Giacco and M. Brownlee, “Oxidative stress and diabetic complications,” Circulation Research, vol. 107, no. 9, pp. 1058–1070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Styskal, H. Van Remmen, A. Richardson, and A. B. Salmon, “Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models?” Free Radical Biology and Medicine, vol. 52, no. 1, pp. 46–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Bansal and R. Kakkar, “Resveratrol: a polyphenol with multiple health benefits,” International Journal of Pharmaceutics and Drug Analysis, vol. 2, no. 3, pp. 174–191, 2014. View at Google Scholar
  40. S. K. Biswas, “Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox?” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 5698931, 9 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. J. M. Forbes and M. E. Cooper, “Mechanisms of diabetic complications,” Physiological Reviews, vol. 93, no. 1, pp. 137–188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Wu, Y. Zhang, X. Ma, N. Zhang, and G. Qin, “The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats,” Molecular Biology Reports, vol. 39, no. 9, pp. 9085–9093, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Elbe, N. Vardi, M. Esrefoglu, B. Ates, S. Yologlu, and C. Taskapan, “Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats,” Human and Experimental Toxicology, vol. 34, no. 1, pp. 100–113, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Kumar, R. K. Kaundal, S. Iyer, and S. S. Sharma, “Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy,” Life Sciences, vol. 80, no. 13, pp. 1236–1244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Kumar, G. Negi, and S. S. Sharma, “Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms,” Current Medicinal Chemistry, vol. 20, no. 36, pp. 4640–4645, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Hua, K. I. Guerin, J. Chen et al., “Resveratrol inhibits pathologic retinal neovascularization in Vldlr−/− mice,” Investigative Ophthalmology and Visual Science, vol. 52, no. 5, pp. 2809–2816, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. H. Kim, Y. S. Kim, G. S. Roh, W. S. Choi, and G. J. Cho, “Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas,” Acta Ophthalmologica, vol. 90, no. 1, pp. e31–e37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. F. G. Soufi, D. Mohammad-nejad, and H. Ahmadieh, “Resveratrol improves diabetic retinopathy possibly through oxidative stress—nuclear factor κB—apoptosis pathway,” Pharmacological Reports, vol. 64, no. 6, pp. 1505–1514, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. O. M. A. Allah and F. El-Debakey, “Prophylactic resveratrol and telmisartan combination ameliorates experimentally-induced diabetic nephropathy in rats, focus on the pro-sclerotic cytokine, transforming growth factor-β1 (TGF-β1),” The Medical Journal of Cairo University, vol. 78, no. 2, 2010. View at Google Scholar
  50. R. K. Vella, C. Pullen, F. R. Coulson, and A. S. Fenning, “Resveratrol prevents cardiovascular complications in the SHR/STZ rat by reductions in oxidative stress and inflammation,” BioMed Research International, vol. 2015, Article ID 918123, 8 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Turan, E. Tuncay, and G. Vassort, “Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies,” Journal of Bioenergetics and Biomembranes, vol. 44, no. 2, pp. 281–296, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Mohammadshahi, F. Haidari, and F. G. Soufi, “Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress,” Cardiology Journal, vol. 21, no. 1, pp. 39–46, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Hamadi, A. Mansour, M. H. Hassan, F. Khalifi-Touhami, and O. Badary, “Ameliorative effects of resveratrol on liver injury in streptozotocin-induced diabetic rats,” Journal of Biochemical and Molecular Toxicology, vol. 26, no. 10, pp. 384–392, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. M. A. Hussein and H. A. El-Maksoud, “Biochemical effects of Resveratrol and curcumin combination on obese diabetic rats,” Molecular & Clinical Pharmacology, vol. 4, no. 1, pp. 1–10, 2013. View at Google Scholar
  55. J. L. Fiori, Y.-K. Shin, W. Kim et al., “Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet,” Diabetes, vol. 62, no. 10, pp. 3500–3513, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. C. R. Ku, H. J. Lee, S. K. Kim, E. Y. Lee, M.-K. Lee, and E. J. Lee, “Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic β-cell and the cleavage of poly (ADP-ribose) polymerase,” Endocrine Journal, vol. 59, no. 2, pp. 103–109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. C.-C. Chang, M.-H. Yang, H.-C. Tung et al., “Resveratrol exhibits differential protective effects on fast- and slow-twitch muscles in streptozotocin-induced diabetic rats,” Journal of Diabetes, vol. 6, no. 1, pp. 60–67, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. H.-C. Su, L.-M. Hung, and J.-K. Chen, “Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats,” American Journal of Physiology—Endocrinology and Metabolism, vol. 290, no. 6, pp. E1339–E1346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. S. V. Penumathsa, M. Thirunavukkarasu, L. Zhan et al., “Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium,” Journal of Cellular and Molecular Medicine, vol. 12, no. 6, pp. 2350–2361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. K. H. Chen, M. L. Cheng, Y. H. Jing, D. T. Chiu, M. S. Shiao, and J. K. Chen, “Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 301, no. 5, pp. E853–E863, 2011. View at Publisher · View at Google Scholar
  61. D. M. Nathan, M. B. Davidson, R. A. DeFronzo et al., “Impaired fasting glucose and impaired glucose tolerance: implications for care,” Diabetes Care, vol. 30, no. 3, pp. 753–759, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. J. A. Baur, K. J. Pearson, N. L. Price et al., “Resveratrol improves health and survival of mice on a high-calorie diet,” Nature, vol. 444, no. 7117, pp. 337–342, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α,” Cell, vol. 127, no. 6, pp. 1109–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. Y.-E. Lee, J.-W. Kim, E.-M. Lee et al., “Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice,” PLoS ONE, vol. 7, no. 11, Article ID e50412, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. M.-S. Beaudoin, L. A. Snook, A. M. Arkell, J. A. Simpson, G. P. Holloway, and D. C. Wright, “Resveratrol supplementation improves white adipose tissue function in a depot-specific manner in Zucker diabetic fatty rats,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 305, no. 5, pp. R542–R551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. J.-H. Um, S.-J. Park, H. Kang et al., “AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol,” Diabetes, vol. 59, no. 3, pp. 554–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Marchal, S. Blanc, J. Epelbaum, F. Aujard, and F. Pifferi, “Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, microcebus murinus,” PLoS ONE, vol. 7, no. 3, Article ID e34289, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. J. R. Zierath and Y. Kawano, “The effect of hyperglycaemia on glucose disposal and insulin signal transduction in skeletal muscle,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 17, no. 3, pp. 385–398, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Pitocco, F. Zaccardi, E. Di Stasio et al., “Oxidative stress, nitric oxide, and diabetes,” Review of Diabetic Studies, vol. 7, no. 1, pp. 15–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Thirunavukkarasu, S. V. Penumathsa, S. Koneru et al., “Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase,” Free Radical Biology and Medicine, vol. 43, no. 5, pp. 720–729, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. Á. González-Rodríguez, B. Santamaría, J. A. Mas-Gutierrez et al., “Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1-independent manner,” Molecular Nutrition and Food Research, vol. 59, no. 8, pp. 1431–1442, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Moridi, J. Karimi, N. Sheikh et al., “Resveratrol-dependent down-regulation of receptor for advanced glycation end-products and oxidative stress in kidney of rats with diabetes,” International Journal of Endocrinology and Metabolism, vol. 13, no. 2, Article ID e23542, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Khazaei, J. Karimi, N. Sheikh et al., “Effects of resveratrol on receptor for advanced glycation end products (RAGE) expression and oxidative stress in the liver of rats with type 2 diabetes,” Phytotherapy Research, vol. 30, no. 1, pp. 66–71, 2016. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Chaudhary and P. T. Pfluger, “Metabolic benefits from Sirt1 and Sirt1 activators,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 4, pp. 431–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. J. C. Milne, P. D. Lambert, S. Schenk et al., “Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes,” Nature, vol. 450, no. 7170, pp. 712–716, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. S. V. De Kreutzenberg, G. Ceolotto, I. Papparella et al., “Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms,” Diabetes, vol. 59, no. 4, pp. 1006–1015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Ramadori, L. Gautron, T. Fujikawa, C. R. Vianna, J. K. Elmquist, and R. Coppari, “Central administration of resveratrol improves diet-induced diabetes,” Endocrinology, vol. 150, no. 12, pp. 5326–5333, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. C. D. Côté, B. A. Rasmussen, F. A. Duca et al., “Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network,” Nature Medicine, vol. 21, no. 5, pp. 498–505, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. B. Bordone and L. Guarente, “Sirtuins and β-cell function,” Diabetes, Obesity and Metabolism, vol. 9, no. 2, pp. 23–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. I. Kitamura, T. Kitamura, J.-P. Kruse et al., “FoxO1 protects against pancreatic β cell failure through NeuroD and MafA induction,” Cell Metabolism, vol. 2, no. 3, pp. 153–163, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Turkmen, A. Karagoz, and A. Kucuk, “Sirtuins as novel players in the pathogenesis of diabetes mellitus,” World Journal of Diabetes, vol. 5, no. 6, pp. 894–900, 2014. View at Publisher · View at Google Scholar
  82. K. Hasegawa, S. Wakino, K. Yoshioka et al., “Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression,” Biochemical and Biophysical Research Communications, vol. 372, no. 1, pp. 51–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. P. T. Pfluger, D. Herranz, S. Velasco-Miguel, M. Serrano, and M. H. Tschöp, “Sirt1 protects against high-fat diet-induced metabolic damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 28, pp. 9793–9798, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. K. A. Moynihan, A. A. Grimm, M. M. Plueger et al., “Increased dosage of mammalian Sir2 in pancreatic β cells enhances glucose-stimulated insulin secretion in mice,” Cell Metabolism, vol. 2, no. 2, pp. 105–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. K. M. Ramsey, K. F. Mills, A. Satoh, and S.-I. Imai, “Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice,” Aging Cell, vol. 7, no. 1, pp. 78–88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Kitada and D. Koya, “SIRT1 in type 2 diabetes: mechanisms and therapeutic potential,” Diabetes and Metabolism Journal, vol. 37, no. 5, pp. 315–325, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. S. S. Kulkarni and C. Cantó, “The molecular targets of resveratrol,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1852, no. 6, pp. 1114–1123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. M.-J. Lee, D. Feliers, M. M. Mariappan et al., “A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy,” American Journal of Physiology—Renal Physiology, vol. 292, no. 2, pp. F617–F627, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. K.-H. Chen, C.-C. Hung, H.-H. Hsu, Y.-H. Jing, C.-W. Yang, and J.-K. Chen, “Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats,” Chemico-Biological Interactions, vol. 190, no. 1, pp. 45–53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. N. L. Price, A. P. Gomes, A. J. Y. Ling et al., “SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function,” Cell Metabolism, vol. 15, no. 5, pp. 675–690, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. C.-C. Chang, C.-Y. Chang, J.-P. Huang, and L.-M. Hung, “Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats,” Chinese Journal of Physiology, vol. 55, no. 3, pp. 192–201, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Schmatz, L. B. Perreira, N. Stefanello et al., “Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats,” Biochimie, vol. 94, no. 2, pp. 374–383, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. K. Carolo dos Santos, C. Pereira Braga, P. Octavio Barbanera, F. R. F. Seiva, A. Fernandes Jr., and A. A. H. Fernandes, “Cardiac energy metabolism and oxidative stress biomarkers in diabetic rat treated with resveratrol,” PLoS ONE, vol. 9, no. 7, Article ID e102775, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Kitada, S. Kume, N. Imaizumi, and D. Koya, “Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway,” Diabetes, vol. 60, no. 2, pp. 634–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Khamneh, F. G. Soufi, and F. Afshar, “Long-term resveratrol administration reduces renal oxidative stress and apoptosis rate in experimental model of type 2 diabetes,” Life Science Journal, vol. 9, no. 4, pp. 2997–3001, 2012. View at Google Scholar · View at Scopus
  96. H. E. Mohamed, S. E. El-Swefy, R. A. Hasan, and A. A. Hasan, “Neuroprotective effect of resveratrol in diabetic cerebral ischemic-reperfused rats through regulation of inflammatory and apoptotic events,” Diabetology & Metabolic Syndrome, vol. 6, no. 1, article 88, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. E. Yulug, S. Tured, A. Alver, O. Kutlu, E. Karaguzel, and C. Kahraman, “Effects of resveratrol on testis damage in streptozotocin induced diabetic rats,” Journal of Animal and Veterinary Advances, vol. 12, no. 6, pp. 747–753, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Jeong, M. J. Conboy, and I. M. Conboy, “Sirt1-independent rescue of muscle regeneration by resveratrol in type I diabetes,” Journal of Diabetes & Metabolism, vol. 4, article 289, 2013. View at Publisher · View at Google Scholar
  99. M. C. Haigis and L. P. Guarente, “Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction,” Genes & Development, vol. 20, no. 21, pp. 2913–2921, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Michan and D. Sinclair, “Sirtuins in mammals: insights into their biological function,” Biochemical Journal, vol. 404, no. 1, pp. 1–13, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. D.-W. Park, K. Baek, J.-R. Kim et al., “Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1,” Experimental and Molecular Medicine, vol. 41, no. 3, pp. 171–179, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. Z. Ungvari, N. Labinskyy, P. Mukhopadhyay et al., “Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 297, no. 5, pp. H1876–H1881, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. L. M. Pedruzzi, M. B. Stockler-Pinto, M. Leite Jr., and D. Mafra, “Nrf2-keap1 system versus NF-κB: the good and the evil in chronic kidney disease?” Biochimie, vol. 94, no. 12, pp. 2461–2466, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. A. A. Elmarakby and J. C. Sullivan, “Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy,” Cardiovascular Therapeutics, vol. 30, no. 1, pp. 49–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. T. Lawrence, “The nuclear factor NF-κB pathway in inflammation,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 6, Article ID a001651, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Kumar and S. S. Sharma, “NF-κB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy,” Biochemical and Biophysical Research Communications, vol. 394, no. 2, pp. 360–365, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. O. Prabhakar, “Cerebroprotective effect of resveratrol through antioxidant and anti-inflammatory effects in diabetic rats,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 386, no. 8, pp. 705–710, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. X.-D. Lou, H.-D. Wang, S.-J. Xia, S. Skog, and J. Sun, “Effects of resveratrol on the expression and DNA methylation of cytokine genes in diabetic rat aortas,” Archivum Immunologiae et Therapiae Experimentalis, vol. 62, no. 4, pp. 329–340, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. S.-M. Lee, H. Yang, D. M. Tartar et al., “Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes,” Diabetologia, vol. 54, no. 5, pp. 1136–1146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. H. Zhang, J. Zhang, Z. Ungvari, and C. Zhang, “Resveratrol improves endothelial function. Role of TNFα and vascular oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 8, pp. 1164–1171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Movahed, I. Nabipour, X. L. Louis et al., “Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 851267, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. P. Brasnyó, G. A. Molnár, M. Mohás et al., “Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients,” British Journal of Nutrition, vol. 106, no. 3, pp. 383–389, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. Y. K. Bashmakov, S. H. Assaad-Khalil, M. Abou Seif et al., “Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients,” ISRN Endocrinology, vol. 2014, Article ID 816307, 8 pages, 2014. View at Publisher · View at Google Scholar
  114. S. Timmers, E. Konings, L. Bilet et al., “Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans,” Cell Metabolism, vol. 14, no. 5, pp. 612–622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. B. Agarwal, M. J. Campen, M. M. Channell et al., “Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium,” International Journal of Cardiology, vol. 166, no. 1, pp. 246–248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. M. M. Poulsen, P. F. Vestergaard, B. F. Clasen et al., “High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition,” Diabetes, vol. 62, no. 4, pp. 1186–1195, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. S. Dash, C. Xiao, C. Morgantini, L. Szeto, and G. F. Lewis, “High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 12, pp. 2895–2901, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. V. S. Chachay, G. A. Macdonald, J. H. Martin et al., “Resveratrol does not benefit patients with nonalcoholic fatty liver disease,” Clinical Gastroenterology and Hepatology, vol. 12, no. 12, pp. 2092–2103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. A. V. Witte, L. Kerti, D. S. Margulies, and A. Flöel, “Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults,” The Journal of Neuroscience, vol. 34, no. 23, pp. 7862–7870, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. M. M. Shahi, F. Haidari, and M. R. Shiri, “Comparison of effect of resveratrol and vanadium on diabetes related dyslipidemia and hyperglycemia in streptozotocin induced diabetic rats,” Advanced Pharmaceutical Bulletin, vol. 1, no. 2, pp. 81–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. A.-S. Cheng, Y.-H. Cheng, C.-Y. Lee, C.-Y. Chung, and W.-C. Chang, “Resveratrol protects against methylglyoxal-induced hyperglycemia and pancreatic damage in vivo,” Nutrients, vol. 7, no. 4, pp. 2850–2865, 2015. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Pereira, E. Park, J. Moore et al., “Resveratrol prevents insulin resistance caused by short-term elevation of free fatty acids in vivo,” Applied Physiology, Nutrition and Metabolism, vol. 40, no. 11, pp. 1129–1136, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. J. Burns, T. Yokota, H. Ashihara, M. E. J. Lean, and A. Crozier, “Plant foods and herbal sources of resveratrol,” Journal of Agricultural and Food Chemistry, vol. 50, no. 11, pp. 3337–3340, 2002. View at Publisher · View at Google Scholar · View at Scopus
  124. C. Counet, D. Callemien, and S. Collin, “Chocolate and cocoa: new sources of trans-resveratrol and trans-piceid,” Food Chemistry, vol. 98, no. 4, pp. 649–657, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. W. J. Hurst, J. A. Glinski, K. B. Miller, J. Apgar, M. H. Davey, and D. A. Stuart, “Survey of the trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products,” Journal of Agricultural and Food Chemistry, vol. 56, no. 18, pp. 8374–8378, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. S. Mukherjee, J. I. Dudley, and D. K. Das, “Dose-dependency of resveratrol in providing health benefits,” Dose-Response, vol. 8, no. 4, pp. 478–500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. K. Bashmakov, S. Assaad-Khalil, and I. M. Petyaev, “Resveratrol may be beneficial in treatment of diabetic foot syndrome,” Medical Hypotheses, vol. 77, no. 3, pp. 364–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Tomé-Carneiro, M. Larrosa, M. J. Yáñez-Gascón et al., “One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease,” Pharmacological Research, vol. 72, pp. 69–82, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. J. Yoshino, C. Conte, L. Fontana et al., “Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance,” Cell Metabolism, vol. 16, no. 5, pp. 658–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. J. P. Crandall, V. Oram, G. Trandafirescu et al., “Pilot study of resveratrol in older adults with impaired glucose tolerance,” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 67, no. 12, pp. 1307–1312, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. C. Militaru, I. Donoiu, A. Craciun, I. D. Scorei, A. M. Bulearca, and R. I. Scorei, “Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life,” Nutrition, vol. 29, no. 1, pp. 178–183, 2013. View at Publisher · View at Google Scholar · View at Scopus
  132. J. Tomé-Carneiro, M. Gonzálvez, M. Larrosa et al., “One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease,” American Journal of Cardiology, vol. 110, no. 3, pp. 356–363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. T. Walle, M. H. De Legge, R. E. Hypolite, J. T. Lucas, and U. K. Walle, “Resveratrol-[C-14] disposition and metabolism in vivo in humans,” The FASEB Journal, vol. 18, no. 4, p. A604, 2004. View at Google Scholar
  134. J. M. Smoliga and O. Blanchard, “Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution?” Molecules, vol. 19, no. 11, pp. 17154–17172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  135. E. L. Wightman, J. L. Reay, C. F. Haskell, G. Williamson, T. P. Dew, and D. O. Kennedy, “Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation,” British Journal of Nutrition, vol. 112, no. 2, pp. 203–213, 2014. View at Publisher · View at Google Scholar · View at Scopus
  136. H. J. Park, J.-Y. Yang, S. Ambati et al., “Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes,” Journal of Medicinal Food, vol. 11, no. 4, pp. 773–783, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. A. Schlachterman, F. Valle, K. M. Wall et al., “Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model,” Translational Oncology, vol. 1, no. 1, pp. 19–27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Rayalam, M. A. Della-Fera, and C. A. Baile, “Synergism between resveratrol and other phytochemicals: implications for obesity and osteoporosis,” Molecular Nutrition & Food Research, vol. 55, no. 8, pp. 1177–1185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  139. C. K. Singh, J. George, and N. Ahmad, “Resveratrol-based combinatorial strategies for cancer management,” Annals of the New York Academy of Sciences, vol. 1290, no. 1, pp. 113–121, 2013. View at Publisher · View at Google Scholar · View at Scopus
  140. K. R. Polley, N. Jenkins, P. O’Connor, and K. McCully, “Influence of exercise training with resveratrol supplementation on skeletal muscle mitochondrial capacity,” Applied Physiology, Nutrition and Metabolism, vol. 41, no. 1, pp. 26–32, 2015. View at Publisher · View at Google Scholar · View at Scopus
  141. C. Chu, F. J. Lu, R. H. Yeh, Z. L. Li, and C. H. Chen, “Synergistic antioxidant activity of resveratrol with genistein in high-glucose treated Madin-Darby canine kidney epithelial cells,” Biomedical Reports, vol. 4, no. 3, pp. 349–354, 2016. View at Google Scholar
  142. R. L. Frozza, A. Bernardi, K. Paese et al., “Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats,” Journal of Biomedical Nanotechnology, vol. 6, no. 6, pp. 694–703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. L. Liang, X. Liu, Q. Wang, S. Cheng, S. Zhang, and M. Zhang, “Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4′-tri-O-acetylresveratrol in rats,” Phytomedicine, vol. 20, no. 6, pp. 558–563, 2013. View at Publisher · View at Google Scholar · View at Scopus